As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity sca
Earlier this month, Eisai and Biogen secured Japanese approval for the at-home LEQEMBI Pen subcutaneous formulation for early Alzheimer’s disease, while Biogen also published Phase 3 VALIANT adolescen
Key Stats for Novo Nordisk StockPrice change for Novo Nordisk stock in last 1 year: -35%$NVO Stock Price as of Sep. 22: $3952-Week High: $64$NVO Stock Price Target: $47What Happened?Novo Nordisk (NVO)
Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly and Company, and Regeneron. With more than 190 live customers and
Biogen (BIIB) is back in focus after publishing adolescent subgroup data from its Phase 3 VALIANT trial of EMPAVELI in rare kidney diseases, a catalyst that gives investors fresh clinical context arou
Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
View interactive chart, options flow, and AI analysis for BIIB on Zorveq Finance.
Open BIIB Chart & Analysis →